Morgan Stanley Actinium Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.59 Trillion
Q3 2025

A detailed history of Morgan Stanley transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 4,719 shares of ATNM stock, worth $6,134. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,719

Previous 44,700 89.44%

Holding current value

$6,134

Previous $62,000 88.71%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$1.4 - $1.86 $55,973 - $74,364	-39,981 Reduced 89.44%	4,719 $7,000
Q2 2025 Aug 15, 2025	SELL	$1.15 - $1.94 $24,216 - $40,852	-21,058 Reduced 32.02%	44,700 $62,000
Q1 2025 May 15, 2025	SELL	$1.06 - $2.12 $159,398 - $318,797	-150,376 Reduced 69.58%	65,758 $105,000
Q4 2024 Feb 14, 2025	BUY	$1.12 - $1.93 $114,736 - $197,714	102,443 Added 90.11%	216,134 $272,000
Q3 2024 May 14, 2025	BUY	$1.72 - $8.0 $33,949 - $157,904	19,738 Added 21.01%	113,691 $213,000

Q3 2024 Nov 14, 2024	BUY	$1.72 - $8.0 $33,949 - $157,904	19,738 Added 21.01%	113,691 $213,000
Q2 2024 May 14, 2025	SELL	$6.56 - $9.89 $801,507 - $1.21 Million	-122,181 Reduced 56.53%	93,953 $695,000
Q2 2024 Oct 17, 2024	BUY	$6.56 - $9.89 $152,828 - $230,407	23,297 Added 32.97%	93,953 $695,000
Q2 2024 Aug 14, 2024	BUY	$6.56 - $9.89 $152,828 - $230,407	23,297 Added 32.97%	93,953 $695,000
Q1 2024 Oct 17, 2024	SELL	$5.0 - $9.2 $116,485 - $214,332	-23,297 Reduced 24.8%	70,656 $553,000
Q1 2024 Aug 16, 2024	SELL	$5.0 - $9.2 $144,455 - $265,797	-28,891 Reduced 29.02%	70,656 $553,000
Q1 2024 May 15, 2024	SELL	$5.0 - $9.2 $144,455 - $265,797	-28,891 Reduced 29.02%	70,656 $553,000
Q4 2023 Aug 16, 2024	BUY	$4.02 - $6.08 $22,487 - $34,011	5,594 Added 5.95%	99,547 $505,000
Q4 2023 Feb 13, 2024	BUY	$4.02 - $6.08 $206,069 - $311,666	51,261 Added 106.16%	99,547 $505,000
Q3 2023 Nov 15, 2023	SELL	$5.91 - $7.37 $68,437 - $85,344	-11,580 Reduced 19.34%	48,286 $285,000
Q2 2023 Aug 14, 2023	SELL	$7.15 - $9.39 $286,135 - $375,778	-40,019 Reduced 40.07%	59,866 $444,000
Q1 2023 May 15, 2023	BUY	$8.51 - $14.26 $505,596 - $847,215	59,412 Added 146.79%	99,885 $943,000
Q4 2022 Feb 14, 2023	SELL	$7.05 - $14.41 $68,377 - $139,762	-9,699 Reduced 19.33%	40,473 $431,000
Q3 2022 Nov 14, 2022	BUY	$4.81 - $8.48 $7,296 - $12,864	1,517 Added 3.12%	50,172 $370,000
Q2 2022 Oct 27, 2022	BUY	$4.71 - $7.11 $133,043 - $200,836	28,247 Added 138.41%	48,655 $234,000
Q2 2022 Aug 15, 2022	BUY	$4.71 - $7.11 $133,043 - $200,836	28,247 Added 138.41%	48,655 $234,000
Q1 2022 Oct 27, 2022	SELL	$4.57 - $6.4 $129,088 - $180,780	-28,247 Reduced 58.06%	20,408 $104,000
Q1 2022 May 13, 2022	SELL	$4.57 - $6.4 $46,435 - $65,030	-10,161 Reduced 33.24%	20,408 $104,000
Q4 2021 Feb 14, 2022	SELL	$6.01 - $8.8 $80,552 - $117,946	-13,403 Reduced 30.48%	30,569 $184,000
Q3 2021 Nov 15, 2021	BUY	$5.76 - $9.67 $253,278 - $425,209	43,972 New	43,972 $390,000

Others Institutions Holding ATNM

# of Institutions

Shares Held

6.8M

Call Options Held

42.3K

Put Options Held

View Full List

About Actinium Pharmaceuticals, Inc.

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $32.7M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

More about ATNM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account